GW Pharmaceuticals PLC

GW is developing cannabis-based pharmaceuticals using extracts taken from plants which are specially bred to optimize the therapeutic benefit of cannabis.

Doctors, scientists and patients alike have long been aware of the therapeutic benefits of cannabis. But few pharmaceutical companies have exploited the plant to make prescription drugs, mainly because of social and political issues surrounding the even-wider known recreational use—and abuse—of cannabis (sold on the streets as marijuana, hashish and pot). With governments all over the world stepping up their battle against illegal drug use, regulatory and legal hurdles to getting a cannabis-derived product on the market were deemed too high for most.

Yet thousands of patients with diseases such as multiple sclerosis, cancer and AIDS continue to use cannabis to relieve their...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip